FDA AD POLICY "UNDERMINES" EFFICACY STANDARD, "INHIBITS" SUPPLEMENTAL APPLICATIONS, EX-FDAer SAYS; SEPARATE STANDARD FOR AD DATA PROPOSED
This article was originally published in The Gray Sheet
Executive Summary
FDA's policy on product advertising "undermines" the efficacy standard by preventing the dissemination of "information on data quality" and forcing the creation of an "underground" system of data dissemination, former agency staffer Jur Strobos, MD, now with the D.C. firm Greenberg, Traurig, states in a policy paper to be released at the Food & Drug Law Institute's educational conference in Washington, D.C. on Dec. 12-13.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.